“Assessment of Patients Affected by Rheumatoid Arthritis Eligible for Biotechnological Agents and Evaluation of Their Healthcare Resource Utilization and Related Costs”. 2021. Reumatismo 73 (1): 5-14. https://doi.org/10.4081/reumatismo.2021.1329.